This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Are Options Traders Betting on a Big Move in Ardent Health Stock?
by Zacks Equity Research
Investors need to pay close attention to Ardent Health stock based on the movements in the options market lately.
ARDTNegative Net Change
medical medical-devices
ISRG Shares Rise as FDA Clears AI Integration for Ion Platform
by Zacks Equity Research
Intuitive Surgical shares climb after FDA clears AI-driven upgrades for its Ion platform, boosting precision and efficiency in lung biopsies.
ISRGNegative Net Change MASINegative Net Change MMSIPositive Net Change WSTNegative Net Change
medical medical-devices
Hims & Hers Expands Personalized Care Access Via Telehealth Platform
by Debanjana Dey
HIMS expands its AI-powered telehealth platform, boosting personalized care and eyeing international growth in 2026.
GDRXNegative Net Change HIMSNegative Net Change LFMDNegative Net Change
medical medical-devices
Can Digital Workflows at Optum Rx Transform UNH's Patient Experience?
by Zacks Equity Research
UnitedHealth drives a digital overhaul at Optum Rx, automating pharmacy workflows to boost efficiency and enrich patient care.
UNHNegative Net Change HUMNegative Net Change ELVNegative Net Change
artificial-intelligence insurance medical
RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes
by Zacks Equity Research
Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection, expanding its reach beyond rare diseases.
SNYPositive Net Change MASINegative Net Change MMSIPositive Net Change RVTYNegative Net Change
medical medical-devices
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
by Ahan Chakraborty
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
If the AI Bubble Bursts, Here Are Some Defensive ETFs to Consider
by Aparajita Dutta
As AI-fueled gains spark bubble warnings, investors are eyeing defensive ETFs in consumer staples, utilities and healthcare for safety.
XLPPositive Net Change XLVPositive Net Change VHTPositive Net Change XLUNegative Net Change VPUNegative Net Change VDCNegative Net Change IDUNegative Net Change IXJPositive Net Change KXINegative Net Change
consumer-staples etfs medical utilities
Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?
by Sridatri Sarkar
Tempus AI sharpens its edge in precision medicine with key acquisitions, strong R&D launches, and improving financials amid rising competition.
LHPositive Net Change GEHCNegative Net Change TEMNegative Net Change
medical
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
by Ekta Bagri
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
AZNPositive Net Change JNJPositive Net Change BDTXNo Net Change
biotechnology biotechs medical pharmaceuticals
CVS Health's Aetna Advances Initiative to Curb Hospital Readmissions
by Moumi Mondal
CVS company, Aetna, expands its Aetna Clinical Collaboration program to 10 hospitals, aiming to cut readmissions and ease hospital workloads.
HUMNegative Net Change CVSNegative Net Change CNCNegative Net Change
medical medical-devices
Brookdale Posts Strong YoY Rise in September 2025 Occupancy
by Zacks Equity Research
BKD's September weighted average consolidated occupancy rate hits 82.5%, up 330 bps YoY. The metric signals a year-over-year rise of 290 bps in third-quarter 2025.
BKDPositive Net Change ANIPNegative Net Change MEDPNegative Net Change EHCNegative Net Change
medical
The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne
by Zacks Equity Research
SAP's cloud and AI push, Novartis' strong drug lineup, and Philip Morris' smoke-free growth headline Zacks' latest analyst picks.
NVSPositive Net Change PMNegative Net Change SAPNegative Net Change CLRONegative Net Change ICCCPositive Net Change
communications computers consumer-staples medical pharmaceuticals
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
by Zacks Equity Research
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change
biotechnology biotechs medical
ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering
by Zacks Equity Research
Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.
RDYPositive Net Change ESPRNegative Net Change SDZNYPositive Net Change
biotechs medical
Top Stock Reports for SAP, Novartis & Philip Morris
by Mark Vickery
SAP, Novartis and Philip Morris headline today's top Zacks reports, each showing strong momentum and strategic growth drivers despite industry headwinds.
NVSPositive Net Change PMNegative Net Change SAPNegative Net Change CLRONegative Net Change ICCCPositive Net Change UBERPositive Net Change NETNegative Net Change HOODNegative Net Change
communications computers consumer-staples medical pharmaceuticals
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL's robust product lineup, innovation-driven growth and strong Q2 results underscore its long-term potential despite macroeconomic headwinds.
ECLNegative Net Change MASINegative Net Change MMSIPositive Net Change WSTNegative Net Change
medical medical-devices
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell
by Zacks Equity Research
PACB expands seqWell partnership to enhance its sequencing workflow offerings with a new multiplexing kit.
RMDNegative Net Change MASINegative Net Change PACBNegative Net Change SOLVNegative Net Change
medical medical-devices
McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio
by Zacks Equity Research
MCK is transforming from a traditional distributor into a specialty-driven healthcare solutions leader, focusing on oncology, biopharma services and automation while preparing to separate its Medical-Surgical unit.
CAHPositive Net Change MCKPositive Net Change CORPositive Net Change
medical medical-devices
ISRG Bets on SP Platform to Capture Rising ASC Procedure Volume
by Indrajit Bandyopadhyay
Intuitive Surgical's SP platform is gaining traction as a cost-efficient, high-throughput option for ASCs, complementing da Vinci 5 in hospitals.
CNMDNegative Net Change ISRGNegative Net Change STENegative Net Change
medical medical-devices
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
by Zacks Equity Research
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
JNJPositive Net Change BAYRYNegative Net Change FOLDNo Net Change SPROPositive Net Change
biotechnology biotechs medical pharmaceuticals
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
by Zacks Equity Research
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
KALANegative Net Change ALLONegative Net Change AKROPositive Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
TLRY Gears Up to Report Q1 Earnings: Cannabis Recovery in Focus
by Zacks Equity Research
Tilray Brands' fiscal first-quarter report is likely to highlight international cannabis gains, European expansion and wellness growth.
EWPositive Net Change INCYPositive Net Change EXASPositive Net Change TLRYNegative Net Change
cannabis earnings medical
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
by Zacks Equity Research
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
BIIBPositive Net Change BMYPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bear of the Day: Oscar Health (OSCR)
by Kevin Cook
Despite a big boost in revenue guidance, analysts reversed course on profitability for this digital insurer
OSCRNegative Net Change
insurance medical
Should You Buy or Sell CURLF Stock Amid Renewed Legalization Hopes?
by Sundeep Ganoria
Curaleaf's shares have soared over 200% on renewed legalization optimism, but domestic weakness and profit hurdles cloud the outlook.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change CURLFNegative Net Change
marijuana medical